Vical Vaxfectin wins International patents
The patent includes composition of the Vaxfectin adjuvant, composition of Vaxfectin-formulated vaccines, and methods for their use. Vical president and CEO Vijay Samant said Vaxfectin was discovered through
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.
Under the agreement, both the parties have invested for combining Selcia’s medicinal and analytical chemistry, with NeuroVive’s research and development programs in mitochondrial medicine. NeuroVive CEO Mikael Bronnegard